"Updated Guidelines for H. pylori Eradication: Optimizing Treatment in the Era of Rising Antibiotic Resistance"
The Global H. pylori Challenge
Helicobacter pylori infection remains one of the most common chronic bacterial infections globally, strongly associated with peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.1
Recent international guidelines emphasize that appropriate eradication therapy is essential to reduce disease burden and prevent gastric cancer.2 However, increasing resistance to commonly used antibiotics such as clarithromycin and levofloxacin has significantly reduced the effectiveness of traditional triple therapy regimens.3
Contemporary recommendations therefore support resistance-guided therapy, preference for bismuth-based quadruple regimens in many regions, and confirmation of eradication following treatment.2,4
Globally prevalent: Affects nearly half the world's population
Group I Carcinogen: IARC classification reflects direct gastric cancer link
Resistance crisis: Clarithromycin & levofloxacin resistance rising globally
New standard: Bismuth quadruple therapy now preferred first-line
Mandatory testing: Eradication confirmation required post-treatment
Why Eradication Matters
Tap each benefit to explore the clinical evidence. Successful eradication offers multidimensional protection across the GI spectrum.
Tap to know more
5 Practice-Changing Updates
Navigate each updated recommendation from the Maastricht VI/Florence Consensus Report and ACG 2024 guidelines.
Rising Global Antibiotic Resistance
Antibiotic resistance is now one of the primary drivers of eradication failure. Resistance to clarithromycin and levofloxacin has increased substantially across multiple regions worldwide.3
Empirical clarithromycin-based triple therapy is no longer recommended in regions where resistance exceeds 15%. Clinicians must check local susceptibility data before prescribing.2
Bismuth Quadruple: The New Standard
Recent international guidelines recommend bismuth-based quadruple therapy as the preferred first-line treatment in many settings due to its consistently higher eradication rates despite growing antibiotic resistance.2
Clinical studies demonstrate superior efficacy over traditional triple therapy, making it the go-to choice in high-resistance regions.9
- ▸ BQT 10 vs 14 days — non-inferior with fewer side effects13
- ▸ Vonaprazan-amoxicillin 10 days — non-inferior to 14-day BQT14
Individualized Treatment Strategy
Modern guidelines emphasize personalized therapy selection. A one-size-fits-all approach is no longer adequate in the era of rising resistance.2
Selection should be based on: previous antibiotic exposure, regional resistance patterns, patient adherence and tolerance, and availability of susceptibility testing. This approach curbs further resistance development while improving success rates.
Confirmation of Eradication: Mandatory
Successful eradication must always be confirmed after completing therapy.2 Post-treatment testing is no longer optional — it is a clinical standard of care.
Testing should be performed at least 4 weeks after therapy completion, and 1–2 weeks after PPI discontinuation to ensure accurate results.2
Gastric Cancer Prevention
Eradication of H. pylori has been shown to reduce gastric cancer incidence, especially in high-risk populations — by up to 35–40% in some studies.10
Population-based screening and eradication strategies are increasingly being explored worldwide, positioning H. pylori treatment as a public health cancer prevention intervention, not just a GI therapy.10
"H. pylori eradication is the most cost-effective strategy for primary prevention of gastric cancer currently available."
Test Your Knowledge
Flip each card to discover the clinical insight behind each key concept.
It's one of the only bacteria classified as a Group I carcinogen — in the same risk category as tobacco — because of its direct causal link to gastric cancer.4
Rising clarithromycin resistance globally has dramatically reduced triple therapy success rates below acceptable levels in many regions.3
Yes — approximately 75% of early-stage gastric MALT lymphomas regress completely with H. pylori eradication alone, without chemotherapy.8
At least 4 weeks after completing therapy, and 1–2 weeks after stopping PPIs — earlier testing risks false-negative results.2
Your Action Checklist
Evidence-based steps every clinician should apply in H. pylori management today.
Evidence Base